Comparative study on the clinical effectiveness of low-concentration cyclosporine eye drops in patients with dry eye disease
Related Experiment Video
Updated: Sep 30, 2026
Comparing Objective Conjunctival Hyperemia Grading and the Ocular Surface Disease Index Score in Dry Eye Syndrome During COVID-19
Published on: May 25, 2022
Jae Hyun Kim1, Hui Kyung Kim1, Young-Joo Shin2
1Department of Ophthalmology, Pusan National University School of Medicine, Busan, South Korea.
Purpose:
This study aimed to evaluate the efficacy and safety of low-concentration, nanoparticle-based cyclosporine eye drops (SCAI-001 0.01% and SCAI-001 0.02%) compared to those of the conventional Restasis® (cyclosporine 0.05%) emulsion for dry eye disease (DED).
Methods:
In this multicenter, randomized, double-blind, Phase 2 trial, patients with DED were assigned to three groups: SCAI-001 0.01%, SCAI-001 0.02%, and Restasis. The primary efficacy endpoint was the change in tear volume after 12 weeks. Secondary efficacy endpoints included changes in tear volume at 4 and 8 weeks, corneal and conjunctival surface staining scores, tear film breakup time (TBUT), standard patient evaluation of eye dryness questionnaire score (SPEED), and ocular surface disease index (OSDI) at 4, 8, and 12 weeks.
Results:
Tear volume increased in all groups at 12 weeks without intergroup differences. SCAI-001 0.01% and SCAI-001 0.02% achieved earlier improvements in tear volume at 4 weeks than that of Restasis, although no significant between-group difference was observed at any time point. Conjunctival surface scores improved in all groups at 4, 8, and 12 weeks, excluding 4 weeks of Restasis. Conjunctival staining improved to a greater extent with SCAI-001 0.01% than with Restasis at weeks 4 and 8. Corneal surface scores, TBUT, SPEED, and OSDI scores improved in all groups at 4, 8, and 12 weeks without intergroup differences.
Conclusions:
Low-concentration cyclosporine (SCAI-001 0.01% and SCAI-001 0.02%) demonstrated efficacy and safety comparable to that of Restasis in improving DED measures.
Trial Registration:
ClinicalTrials.gov Identifier: NCT05733624.
